Today: 11 April 2026
Subscribe
Browse Category

Pharmaceuticals 10 December 2025 - 13 December 2025

Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Eli Lilly shares closed at $1,027.51 Friday, up about 3% for the week after late-stage trial data showed its obesity drug retatrutide delivered nearly 29% average weight loss in patients with knee osteoarthritis. The stock rebounded from an early-week dip, outperforming the broader market as investors weighed drug tolerability and future pricing strategy.
13 December 2025
···
Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

The FDA approved Milestone Pharmaceuticals’ CARDAMYST nasal spray for on-demand treatment of PSVT in adults, marking the first new U.S. therapy for the condition in over 30 years. The company expects CARDAMYST in pharmacies by Q1 2026. MIST shares were volatile ahead of the decision and ended the week lower despite the approval.
13 December 2025
··
Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly shares closed at $1,027.51, up 1.8% Friday, and traded near $1,028–$1,029 after hours following a European regulatory panel’s recommendation to expand Mounjaro use to children 10 and older with type 2 diabetes. Volume was about 3.2 million shares. The stock remains 7.6% below its 52-week high set in late November.
12 December 2025
··
Merck (MRK) Stock News Today: Winrevair EU Expansion, Keytruda Patent Headwinds, Analyst Forecasts and What Investors Watch (Dec. 12, 2025)

Merck (MRK) Stock News Today: Winrevair EU Expansion, Keytruda Patent Headwinds, Analyst Forecasts and What Investors Watch (Dec. 12, 2025)

Merck shares rose 0.69% to $99.69 by midday Friday after the European Medicines Agency’s CHMP recommended expanded approval for WINREVAIR in pulmonary arterial hypertension. The stock remains about 6% below its late-November high. Investors weighed the regulatory boost against ongoing legal issues for Keytruda and shifting vaccine policy headlines. Merck expects a final EU decision on WINREVAIR in early 2026.
12 December 2025
···
Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Milestone Pharmaceuticals shares closed at $2.95 on Dec. 11, up 10.49% with about 7.54 million shares traded, ahead of an FDA decision on CARDAMYST nasal spray for PSVT due Dec. 13. The stock traded around $2.98 pre-market Dec. 12, rebounding from a 52-week low of $0.625 after an FDA rejection earlier in 2025 and subsequent resubmission.
12 December 2025
·
Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly shares traded near $1,009 Friday after its obesity drug retatrutide showed 28.7% average weight loss in a Phase 3 trial, though with notable discontinuation rates. Reuters reported FDA leaders pushed to speed review of Lilly’s oral GLP-1 drug orforglipron, raising internal concerns. The company is building a $6 billion Alabama plant to boost manufacturing. Analyst price targets remain supportive but vary widely.
12 December 2025
··
Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly shares closed Thursday near $1,006 after new Phase 3 data showed its obesity drug retatrutide cut body weight by up to 28.7% in patients with knee osteoarthritis. The company announced a $6 billion plant in Alabama and reported Q3 revenue up 54% to $17.6 billion. Mounjaro will be covered by China’s national health insurance from January.
11 December 2025
···
Centessa Pharmaceuticals (CNTA) Stock on December 11, 2025: CEO Shake‑Up, Analyst Upgrades and 2026 Orexin Catalysts

Centessa Pharmaceuticals (CNTA) Stock on December 11, 2025: CEO Shake‑Up, Analyst Upgrades and 2026 Orexin Catalysts

Centessa Pharmaceuticals announced Mario Alberto Accardi will become CEO on January 1, 2026, as the company’s orexin drug program nears pivotal studies. Shares fell 8.4% to about $27 after the news. Current CEO Saurabh Saha will move to an advisory role. The company’s lead candidate, ORX750, is set for registrational trials in early 2026.
11 December 2025
··
Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals shares fell 6% to US$9.33 in New York on December 11, near a 52-week low, despite trailing 12-month revenue of US$664 million and a new clinical partnership with Varian. The company faces SEC scrutiny, an FDA setback, and multiple class-action lawsuits, but continues to report late-stage oncology progress and expanding collaborations.
11 December 2025
···
Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant shares rose 9% to $25.75 Thursday after the company announced a $550 million common stock offering to fund development and possible launch of its lead drug, IMVT‑1402, for Graves’ disease. The offering priced at $21 per share, an 11% discount, and is expected to close December 12. Roivant Sciences will participate. Immunovant’s market value reached about $4 billion.
11 December 2025
····
AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie shares rebounded 2.98% to $236.28 on Nov. 21, 2025, with trading volume spiking to 7.9 million after three down days. Year-to-date, the stock is up about 22–26%, outpacing the S&P 500, but remains 7–9% below its October high. Forward P/E estimates range from 16x to 22x. Investors weigh strong Skyrizi and Rinvoq sales against Humira declines and regulatory risk.
11 December 2025
···
Eli Lilly (LLY) Stock After the $1 Trillion Milestone: Latest News, Analyst Targets and 2026 Outlook

Eli Lilly (LLY) Stock After the $1 Trillion Milestone: Latest News, Analyst Targets and 2026 Outlook

Eli Lilly became the first pharmaceutical company to surpass a $1 trillion market value on November 21, 2025, driven by strong demand for its obesity and diabetes drugs. By December 11, shares traded near $993, with a market cap of about $890 billion, down from the peak. The company’s stock is up over 550% in five years, far outpacing the S&P 500. Investors are now focused on valuation rather than growth.
11 December 2025
··
Pfizer (PFE) Stock Premarket Today, Dec. 11, 2025: Marshall Wace Exit, Obesity Drug Deals and 2026 Guidance in Focus

Pfizer (PFE) Stock Premarket Today, Dec. 11, 2025: Marshall Wace Exit, Obesity Drug Deals and 2026 Guidance in Focus

Pfizer shares traded near $25.78 early Thursday, flat from Wednesday’s close, after hedge fund Marshall Wace disclosed a 96.8% reduction in its stake. The stock remains over 50% below its December 2021 high. Pfizer’s 52-week range is $20.92 to $27.69, with a market cap near $147 billion and a dividend yield around 6.7%.
11 December 2025
··
Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

Pfizer shares traded near $25.5 on December 10, up less than 1% but still over 50% below their 2021 peak. The company announced a $2.1 billion obesity-drug partnership with China’s YaoPharma, reported Phase 3 wins for TUKYSA and HYMPAVZI, and confirmed new job cuts in Switzerland. Dividend yield stands near 6.7%. Pfizer reaffirmed 2025 adjusted EPS guidance at $3.00–$3.15.
10 December 2025
··
Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know

Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know

Olema Pharmaceuticals (NASDAQ: OLMA) surged over 11% to $29.68 on December 10, 2025, hitting a new 52-week high amid heavy trading. The rally followed positive Phase 3 data from Roche’s breast cancer drug trial, which boosted confidence in Olema’s own SERD candidate. Year-to-date, OLMA shares have climbed over 400%, with market cap reaching $2.37 billion.
10 December 2025
·
Merck (MRK) Stock on December 10, 2025: Price Action, Dividend Catalyst, Analyst Targets and the Keytruda Question

Merck (MRK) Stock on December 10, 2025: Price Action, Dividend Catalyst, Analyst Targets and the Keytruda Question

Merck shares traded near $97.31 Wednesday afternoon, up slightly after Tuesday’s 2% drop. Volume topped 3.2 million as investors tracked dividend moves and new analyst upgrades. The stock remains about 25% below 2024 highs despite a 41% six-month rally. Signs of rising competition to Keytruda and looming patent pressures weighed on sentiment.
10 December 2025
··
Johnson & Johnson (JNJ) Stock on December 10, 2025: Pipeline Breakthroughs, Talc Risks and What Analysts Expect Next

Johnson & Johnson (JNJ) Stock on December 10, 2025: Pipeline Breakthroughs, Talc Risks and What Analysts Expect Next

Johnson & Johnson shares rose nearly 2% to about $204 on December 10, 2025, after new Phase 3 data showed its Tecvayli and Darzalex combo cut the risk of multiple myeloma progression or death by 83%. The company has filed for FDA approval, while investors weigh growth in oncology against ongoing talc litigation. JNJ stock is up over 38% year to date, outpacing healthcare peers.
10 December 2025
···
Merck Stock (MRK) Today – Keytruda Developments, Analyst Price Targets and 2025–2026 Forecast

Merck Stock (MRK) Today – Keytruda Developments, Analyst Price Targets and 2025–2026 Forecast

Merck shares traded near $97.27 late December 10, 2025, up about 20% over the past month on strong clinical trial results and optimism for new products like Winrevair. Analysts at HSBC, Guggenheim, Scotiabank, and Goldman Sachs raised 12-month price targets to $120–$125. Merck’s market value stands at $240–245 billion, with a dividend yield of about 3.4–3.6%.
10 December 2025
···
Novo Nordisk A/S (NVO) Stock Today: Akero Deal, GLP‑1 Competition and Analyst Downgrades – What 10 December 2025 Means for Investors

Novo Nordisk A/S (NVO) Stock Today: Akero Deal, GLP‑1 Competition and Analyst Downgrades – What 10 December 2025 Means for Investors

Novo Nordisk shares rose about 3–4% to $48 in New York trading on December 10 after months of steep losses. The move followed an Argus downgrade to Hold, citing GLP-1 market-share erosion and underwhelming trial results. Novo has submitted a higher-dose Wegovy application to the FDA. Shares remain down nearly 59% over the past year.
10 December 2025
··
Teva Pharmaceutical Industries (TEVA) Stock: FDA Filing, Analyst Upgrades and 2026–27 Outlook on December 10, 2025

Teva Pharmaceutical Industries (TEVA) Stock: FDA Filing, Analyst Upgrades and 2026–27 Outlook on December 10, 2025

Teva shares traded near $29, close to 52-week highs, after filing a new FDA application for a once-monthly schizophrenia drug and receiving analyst upgrades. Market cap stands at about $32–33 billion. The company reported improved debt ratios and expects consensus 2025 EPS of $2.70. Technical indicators show the stock as overbought but still in an uptrend.
10 December 2025
··
1 … 26 27 28 29 30 … 38

Stock Market Today

  • Jim Cramer Warns of Overconfidence in Market After U.S.-Iran Ceasefire
    April 11, 2026, 7:01 AM EDT. CNBC's Jim Cramer cautioned investors that the stock market is "incredibly overconfident" following a sharp rally after the U.S.-Iran ceasefire announcement. The S&P 500 surged 3.6% last week, fueled by President Trump's two-week pause on Iranian strikes. Despite the relief rally, Cramer warned the ceasefire is fragile and the Middle East situation remains precarious, with risks such as the Strait of Hormuz still unresolved. He advised caution, noting no systemic risk but stressing the market's reaction may be premature. Looking ahead, Cramer will focus on upcoming earnings from major banks like Goldman Sachs and Wells Fargo, highlighting Goldman's potential gain from market volatility. He also mentioned Johnson & Johnson's earnings as a stock to watch, given its history of volatility and strong pipeline.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 7:09 AM EDT Jim Cramer Warns of Overconfidence in Market After U.S.-Iran Ceasefire April 11, 2026, 7:01 AM EDT. CNBC's Jim Cramer cautioned investors that the stock market is "incredibly overconfident" following a sharp rally after the U.S.-Iran ceasefire announcement. The S&P 500 surged 3.6% last week, fueled by President Trump's two-week pause on Iranian strikes. Despite the relief rally, Cramer warned the ceasefire is fragile and the Middle East situation remains precarious, with risks such as the Strait of Hormuz still unresolved. He advised caution, noting no
UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 11:59 PM EDT Orora ASX:ORA Faces Earnings Reset After Saverglass Impact and Middle East Disruptions April 10, 2026, 11:59 PM EDT. Orora (ASX:ORA) shares plunged over 8% in one day following a guidance update that revealed an earnings reset at its Saverglass unit due to Middle East supply chain disruptions and a shutdown at the Ras Al Khaimah glass plant. Despite a sharp short-term loss, Orora's 90-day share price rise exceeds 33%, contrasting a longer-term 10.58% annual total shareholder return decline amid ongoing sector pressures. Trading at A$1.49,
Go toTop